Search

Displaying results 3101 - 3110 of 8171 in total
  1. Drug

    Penicillamine

    go.drugbank.com/drugs/DB00859
    ApprovedInvestigational

    The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine). … It is an α-amino acid metabolite of penicillin, although it has no antibiotic properties.

    Synonyms: D-penicillamine, 3-mercapto-D-valineProducts: D-Penamine
  2. Drug

    Tafamidis

    go.drugbank.com/drugs/DB11644
    ApprovedInvestigational

    [A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]

  3. Drug

    Moxisylyte

    go.drugbank.com/drugs/DB09205
    Approved

    Moxisylyte, denominated as thymoxamine in the UK, is a specific and orally active α1-adrenergic antagonist. According to the WHO, moxisylyte is approved since 1987 and in the same year, it acquired the denomination of orphan product by t...

  4. Drug

    Clobutinol

    go.drugbank.com/drugs/DB09004
    ApprovedWithdrawn

    Clobutinol is a cough suppressant that is withdrawn from the US and EU markets. Clobutinol may prolong the QT interval. In 2007, Clobutinol was determined to cause cardiac arrhythmia in some patients.

  5. Drug

    R1295

    go.drugbank.com/drugs/DB05122
    Experimental

    R1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis.

  6. Drug

    Caroxazone

    go.drugbank.com/drugs/DB09254
    ApprovedWithdrawn

    Caroxazone is an antidepressant that has been withdrawn from the market. It is a reversible monoamine oxidase inhibitor (MAOI) of both A and B monoamine oxidase subtypes.

  7. Drug

    Ropivacaine

    go.drugbank.com/drugs/DB00296
    ApprovedInvestigational

    Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  8. Drug

    JSM 6427

    go.drugbank.com/drugs/DB06139
    Investigational

    JSM 6427 is the first small molecule alpha5beta1 integrin receptor antagonist of its kind to be developed. It has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness ...

  9. Drug

    AC-100

    go.drugbank.com/drugs/DB05671
    Investigational

    AC-100 is a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells (a fragment from matrix extracellular phosphoglycoprotein).

  10. Drug

    IDM-4

    go.drugbank.com/drugs/DB05438
    Experimental

    IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia. … It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes.